programme overview - hiv & hep...

4

PROGRAMME OVERVIEW

5

Sat

ellit

e S

ymp

osi

aC

ong

ress

Ple

nary

Pro

gra

mm

e K

eyno

te L

ectu

res

Ref

resh

men

ts/P

ost

ers

FR

I20

AP

RIL

Ind

ustr

yS

atel

lite

Sym

po

sium

Coffee

Keynote Lecture

Plenary Session

Sci

entifi

c

Po

ster

s an

d L

unch

Ple

nary

and

O

ral P

aper

Coffee

Oral Paper

Ple

nary

Ses

sio

n

Ple

nary

an

d

Ora

l P

aper

Coffee

Industry Satellite

Symposium

Poster Reception

SAT

21 A

PR

IL

Inte

ract

ive

Cas

e S

tud

yS

essi

on

in

colla

bo

ratio

n w

ith

IAS

–US

A

Coffee

Ses

sio

n in

co

llab

ora

tion

with

PA

HO

Coffee

Ses

sio

n in

co

llab

ora

tion

with

IAS

Offi cial Close

Lunc

h

TH

UR

S19

AP

RIL

Offi cial Opening

Ple

nary

S

essi

on

Coffee

Key

note

Le

ctur

esP

lena

ry a

nd

Ora

l Pap

er

Sci

entifi

c

Po

ster

s an

d L

unch

Key

note

Le

ctur

es

Ple

nary

an

d O

ral

Pap

er

Coffee

Ind

ustr

yS

atel

lite

Sym

po

sium

Poster Reception

Tim

e08

.00

09.0

010

.00

11.0

012

.00

13.0

014

.00

15.0

016

.00

17.0

018

.00

19.0

0

Tim

e08

.00

09.0

010

.00

11.0

012

.00

13.0

014

.00

15.0

016

.00

17.0

018

.00

19.0

0

66

SCIENTIFIC PROGRAMME

Thursday 19 April 2018

09.00–09.15 Official Opening

Co-Chairs: Mauro Schechter, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil Juan Sierra-Madero, Instituto Nacional de Ciencias Médicas y Nutrición,

Salvador Zubirán, Mexico City, Mexico

O11 09.15–10.45 Role of Integrase Inhibitors in LATAM: Are We Ready for First Line? Session Supported by an Independent Educational Grant from ViiV Healthcare

O11CH Co-Chairs: Mauro SchechterO11CH Juan Sierra-Madero

O111 09.15–09.35 Current role of integrase inhibitors in Latin American guidelines Ernesto Martínez-Buitrago, Infectious Diseases, Santiago de Cali, Colombia

O112 09.35–09.55 Observational studies with integrase inhibitors and experience with first-line use in Brazil Ricardo Sobhie Diaz, Federal University of São Paulo, São Paulo, Brazil

O113 09.55–10.15 The public health response to rising pretreatment HIV drug resistance levels in Latin America: the case of Mexico Santiago Ávila Ríos, Centre for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico

10.15–10.45 Discussion

10.45–11.00 Coffee

KL11 11.00–12.00 Keynote Lectures

KL11CH Co-Chairs: Anton Pozniak, Chelsea and Westminster Hospital, London, UKKL11CH Mónica Thormann, Salvador B Gautier Hospital, Santo Domingo,

Dominican Republic

KL111 11.00–11.30 What is needed to end HIV/AIDS? Demetre Daskalakis, New York City Department of Health and Mental Hygiene, New York, NY, USA

KL112 11.30–12.00 What do we mean in our region by ending AIDS? Jean W Pape, Les Centres, GHESKIO, Port-au-Prince, Haiti, and Center for Global Health, Division of Infectious Diseases, Weill Cornell Medicine, Cornell University, New York, NY, USA

O12 12.00–13.30 TB Diagnosis and Treatment: An Update for the Region

O12CH Co-Chairs: Massimo N Ghidinelli, Pan American Health Organization, Washington, DC, USAO12CH Marcelo Losso, Hospital General de Agudos JM Ramos Mejía, Buenos Aires,

Argentina

O121 12.00–12.20 New methods for TB diagnosis Rafael López, Tuberculosis Prevention, Control and Elimination, Pan American Health Organization (PAHO), Washington, DC, USA

O122 12.20–12.40 Treatment for drug-resistant TB Anton Pozniak

6 7

SCIENTIFIC PROGRAMME (continued)

O123 12.40–12.55 First-hand experience from Brazil: lessons learned Ezio Távora dos Santos-Filho, Grupo Pela Vida-RJ, Rio de Janeiro, Brazil

O124* 12.55–13.10 Safety and efficacy of dolutegravir-based ART in TB/HIV co-infected adults at Week 24 Eduardo Ticona, Tropical and Infectious Diseases, Hospital Dos de Mayo, Lima, Peru


13.30–14.45 Scientific Posters and Lunch

KL12 14.45–15.45 Keynote Lectures

KL12CH Co-Chairs: Pedro Cahn, Fundación Huésped, Buenos Aires, ArgentinaKL12CH Patricia Volkow, National Institute of Cancer, Mexico City, Mexico

KL121 14.45–15.15 The microbiome in HIV infection Sandra Pinto-Cardoso, Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico

KL122 15.15–15.45 Early treatment of HIV in infants Karin A Nielsen, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA

O13 15.45–16.40 Women with HIV in Latin America

O13CH Co-Chairs: Pedro CahnO13CH Patricia Volkow

O131 15.45–16.05 Diagnosis and treatment of HIV-positive women with comorbidities Mónica Mantilla Suárez, CEPAIN IPS, and Virrey Solís IPS, Bogotá, Colombia

O132 16.05–16.25 ARV safety in pregnancy Vanessa Rouzier, Integrated Care Center and Research Institution, Les Centres, GHESKIO,

Port-au-Prince, Haiti

O133* 16.25–16.40 HIV-infected pregnant adolescents are an extremely vulnerable population: a cohort study of PMTCT outcomes in Haiti Marie M Deschamps, GHESKIO, Port-au-Prince, Haiti

16.40–17.00 Coffee

SS1 17.00–18.30 Challenging the Status Quo of HIV in the Americas Gilead Sciences Satellite Symposium

SS1CH Chair: Luis Soto-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico

SS1CH 17.00–17.05 Introduction Luis Soto-Ramirez

SS11 17.05–17.30 Current situation of regional efforts at screening, diagnosing and linking to care Ernesto Martínez-Buitrago

SS12 17.30–17.55 The current and future status of regional ART guidelines Alejandro Afani, Immunology Section, Department of Medicine, Clinical Hospital, University of Chile, Santiago de Chile, Chile

*Abstract accepted for oral presentation. See page 12 for full author listing.

88


SS13 17.55–18.20 The value of INSTI- and TAF-containing STRs in both naïve and switch patients Luis Soto-Ramirez

18.20–18.30 Discussion All faculty, led by Luis Soto-Ramirez

18.30–19.15 Welcome Reception and Posters

Friday 20 April 2018

SS2 09.00–10.30 Integrated HIV Management: Know Your Patients and Their Needs Merck Sharp & Dohme Satellite Symposium

SS2CH Chair: Mauro Schechter

SS2CH 09.00–09.10 Opening and welcome Mauro Schechter

SS2CH 09.10–09.30 Comorbidities and the need for total patient care Mauro Schechter

SS21 09.30–09.50 How resistance patterns influence individual treatment choices José Luis Blanco, Hospital Clinic Universitari Barcelona, Barcelona, Spain

SS22 09.50–10.10 The importance of tailoring HIV regimens to the individual patient Pedro Cahn

SS23 10.10–10.25 Clinical cases/faculty round table discussion All faculty, led by Mauro Schechter

SS2CH 10.25–10.30 Closing remarks Mauro Schechter

10.30–10.45 Coffee

KL21 10.45–11.15 Keynote Lecture

KL21CH Co-Chairs: Ernesto Martínez-BuitragoKL21CH Ian Weller, University College London Medical School, London, UK

KL211 10.45–11.15 Update on PEP and on its role in the era of PrEP Dawn K Smith, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

O21 11.15–11.55 HIV and Vulnerable Populations

O21CH Co-Chairs: Ernesto Martínez-BuitragoO21CH Ian Weller

O211 11.15–11.35 Transgender people Benjamim Braga, Cuiabá, Brazil

O212 11.35–11.55 Adolescents Daisy Machado, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil

11.55–13.00 Scientific Posters and Lunch

8 9


O22 13.00–14.45 Hepatitis C. New Drugs and What Can We Learn from HIV?

O22CH Co-Chairs: Mario Pessoa, University of São Paulo, São Paulo, BrazilO22CH Alicia Piñeirúa-Menendez, Clinica Especializada Condesa Iztapalapa,

Mexico City, Mexico

O221 13.00–13.20 New HCV drugs in the region Mark Nelson, Chelsea and Westminster Hospital, London, UK

O222 13.20–13.40 Home/self-testing: when, to whom? Experience from HIV Omar Sued, Fundación Huésped, Buenos Aires, Argentina

O223 13.40–14.00 Translating lessons from HIV to hepatitis C Jorge L Santana, University of Puerto Rico School of Medicine, San Juan, Puerto Rico

O224* 14.00–14.15 Risk factors for transmission of hepatitis C virus among the HIV population in Central Mexico: a case-control study Luis Esteban Ramírez-Gonzalez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico


14.45–15.15 Coffee

O23 15.15–15.30 Submitted Abstract

O23CH Chair: Roy M Gulick, Weill Cornell Medicine, New York, NY, USA

O231* 15.15–15.30 Switch to bictegravir/F/TAT from DTG and ABC/3TC Monica Mora, Gilead Sciences Inc, Foster City, CA, USA

O24 15.30–17.00 State-of-the-ART

O24CH Co-Chairs: Carlos J Beltrán, Hospital Barros Luco Trudeau, and University of Santiago, Santiago, Chile

O24CH Roy M Gulick

O241 15.30–15.50 Dual therapy Pedro Cahn

O242 15.50–16.20 HIV and new drugs Daniel R Kuritzkes, Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

O243 16.20–17.00 Round table discussion All faculty, led by Roy M Gulick, and joined by Mauro Schechter and Juan Sierra-Madero


1010


O25 17.00–17.45 Submitted Abstract and CROI Review

O25CH Chair: Ricardo Sobhie Diaz

O251* 17.00–17.15 Transmitted drug resistance trends in individuals with recent infection in the Mesoamerican Region Daniela Tapia-Trejo, Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico

O252 17.15–17.45 Key Data from CROI 2018 Luis Soto-Ramirez

17.45–18.00 Coffee

SS3 18.00–19.00 Towards a Hepatitis C Elimination Program: A New Simple Pangenotypic Regimen Gilead Sciences Satellite Symposium

SS3CH Chair: Juan Sierra-Madero

SS3CH 18.00–18.05 Introduction Juan Sierra-Madero

SS31 18.05–18.25 HCV elimination program: strategies in Latin America Mario Pessoa

SS32 18.25–18.45 Pangenotypic regimen: a step forward in HCV treatment Adrian Gadano, University of Buenos Aires, Buenos Aires, Argentina

18.45–19.00 Discussion Led by Juan Sierra-Madero

19.00–19.45 Reception and Posters

Saturday 21 April 2018

CS1 09.00–10.30 Challenging Cases in HIV Interactive Case Study Session in Collaboration with the International Antiviral Society-USA (IAS-USA)

CS1CH Moderator: Roy M Gulick

CS11 09.00–09.30 What to start? Brenda Crabtree-Ramírez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico

CS12 09.30–10.00 Treatment failure Carlos J Beltrán


10 11


CS13 10.00–10.30 PrEP Kenneth Mayer, Fenway Community Health Center, Boston, MA, USA

Panellists: Carlos J Beltrán Brenda Crabtree-Ramírez Roy M Gulick Kenneth Mayer

10.30–10.45 Coffee

O31 10.45–12.15 Perspectives in Public Health: Old STIs – New Challenges In Collaboration with the Pan American Health Organization (PAHO)

O31CH Chair: Massimo N GhidinelliO31CH Facilitator: Maeve B Mello, Pan American Health Organization, Washington, DC, USA

O311 10.45–11.05 Historic perspectives and public health significance of syphilis and other sexually transmitted infections Massimo N Ghidinelli and Maeve B Mello

O312 11.05–11.20 Syphilis among key populations Mary Kamb, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

O313 11.20–11.35 Innovation: community-based STI clinic and interventions in San Francisco Jeffrey Klausner, Ronald Reagan UCLA Medical Center, and Zuckerberg San Francisco General Hospital and Trauma Center, Los Angeles, CA, USA

O314 11.35–11.50 Outcomes of HIV and syphilis infection among pregnant women in Haiti Marie M Deschamps


12.15–12.30 Coffee

O32 12.30–14.15 Update on Pre-Exposure Prophylaxis (PrEP) In Collaboration with the International AIDS Society (IAS)

O32CH Co-Chairs: Brenda Crabtree-RamírezO32CH Mauro Schechter

O321 12.30–12.50 PrEP: from clinical trials to implementation Kenneth Mayer

O322 12.50–13.10 HIV prevention: PrEP situation in Latin American countries Giovanni Ravasi, Pan American Health Organization (PAHO), Washington, DC, USA

O323 13.10–13.30 PrEP of HIV in Mexico: adding colour to the prevention palette Hugo López-Gatell, National Institute of Public Health, Mexico City, Mexico

13.30–14.15 Discussion/debate

14.15–14.30 Conference Close

14.30–15.15 Lunch

12


Submitted abstracts accepted for oral presentation within the Scientific Programme, illustrating full author group and affiliations.

O124 Safety and efficacy of dolutegravir-based ART in TB/HIV co-infected adults at Week 24 K Dooley1; R Kaplan2; TN Mwelase3; B Grinsztejn4; E Ticona*5; M Lacerda6; P Cahn7; E Belonosova8; M Ait-Khaled9; K Angelis10; D Brown11; R Singh12; C Talarico13; M Aboud14

1Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Infectious Disease, Desmond Tutu HIV Foundation, Cape Town, South Africa; 3Clinical HIV Research Unit, Johannesburg, South Africa; 4Infectious Disease, Instituto de Pesquisa Clínica Evandro Chagas Fiocruz, Rio de Janeiro, Brazil; 5Tropical and Infectious Diseases, Hospital Dos de Mayo, Lima, Peru; 6Fiocruz/Tropical Medicine Foundation Dr Heitor, Manaus, Brazil; 7Fundación Huesped, Buenos Aires, Argentina; 8Regional Center for Prevention and Treatment of AIDS and Infectious Diseases, Moscow, Russian Federation; 9Clinical Development, ViiV Healthcare, Brentford, UK; 10Statistics, GlaxoSmithKline, Stockley Park, UK; 11Clinical Pharmacology, ViiV Healthcare, Abbotsford, Australia; 12Global Medical Dolutegravir, GlaxoSmithKline, Upper Merion, PA, USA; 13Clinical Development, ViiV Healthcare, Research Triangle Park, NC, USA; 14Global Medical Dolutegravir, ViiV Healthcare, Research Triangle Park, NC, USA

O133 HIV-infected pregnant adolescents are an extremely vulnerable population: a cohort study of PMTCT outcomes in Haiti MM Deschamps*1; V Rouzier2; D Jannat-Khah3; J Bonhomme4; J Pierrot5; L Reif6; JW Pape1; M McNairy6

1GHESKIO, Port-au-Prince, Haiti; 2Paediatrics, GHESKIO, Port-au-Prince, Haiti; 3General Internal Medicine, Weill Cornell Medicine, New York, NY, USA; 4Obstetrics, GHESKIO, Port-au-Prince, Haiti; 5Data Management, GHESKIO, Port-au-Prince, Haiti; 6Center for Global Health, Weill Cornell Medicine, New York, NY, USA

O224 Risk factors for transmission of hepatitis C virus among the HIV population in Central Mexico: a case-control study LE Ramírez-Gonzalez*1; A Piñeirúa-Menendez2; JF Sanchez-Avila3; AH Hirata-Hernandez4; A Camiro-Zuñiga1; E Simental-Aldaba1; I Zamora-Tapia1; J Sierra-Madero1

1Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico; 2HIV, Clinica Codnesa Iztapalapa, Mexico City, Mexico; 3Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico; 4Mental Health, Clinica Condesa Iztapalapa, Mexico City, Mexico

O231 Switch to bictegravir/F/TA from DTG and ABC/3TC J-M Molina1; D Ward2; HJ Stellbrink3; D Podzamczer4; C Brinson5; K Andreatta6; H Martin6; A Cheng6; M Mora*6; E Quirk6

1Hopital Saint Louis, Paris, France; 2Dupont Circle Physicians, Washington, DC, USA; 3ICH Study Center, Hamburg, Germany; 4Hospital Universitari de Bellvitge, Barcelona, Spain; 5Central Texas Clinical Research, Austin, TX, USA; 6Gilead Sciences Inc, Foster City, CA, USA

O251 Transmitted drug resistance trends in individuals with recent infection in the Mesoamerican Region D Tapia-Trejo*1; S Ávila Ríos1; C García Morales1; R Pinzón Meza2; J Miguel Pascale3; G Porras Cortes4; C Quant Durán5; I Lorenzana6; RI Meza Martínez7; E Yolanda Palou8; G Reyes Terán1

1Center for Research in Infectious Diseases (CIENI), National Institute of Respiratory Diseases (INER), Mexico City, Mexico; 2Infectious Disease Clinic, Hospital Roosevelt, Guatemala City, Guatemala; 3Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá, Panama; 4Hospital Vivian Pellas, Managua, Nicaragua; 5Hospital Roberto Calderón, Managua, Nicaragua; 6Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras; 7Laboratorio Nacional de VIH, Tegucigalpa, Honduras; 8Instituto Nacional Cardio-Pulmonar, Tegucigalpa, Honduras

*Indicates presenting author.

AdvancingTherapeutics,Improving Lives.

For 30 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.

GILEAD IS A PROUD SUPPORTER OF THE HIV & HEPATITIS IN THE AMERICAS 2018 CONGRESS.

For more information, please visit www.gilead.com.© 2018 Gilead Sciences, Inc.

14

POSTER PRESENTATIONS


All Scientific Posters have been arranged into the following categories and numbers:

Category Poster number

Comorbidities and Complications of Disease and/or Treatment P001–P010 HIV/Hepatitis Co-infection P011–P017HIV and Tuberculosis P019–P021HIV and Women, Including MTCT P022–P023HIV and Vulnerable Populations P024–P033Models of Care/Scale-Up of Treatment P035–P043Non-AIDS Morbidities and Mortality, and Ageing P044–P046Treatment Strategies and Outcomes P047–P054Viral Hepatitis P055–P064Virology and Immunology P065–P066

Comorbidities and Complications of Disease and/or Treatment

P001 Dynamics of CD4 lymphocytes in patients infected by HIV with non-Hodgkin lymphoma Alatorre Fernández, P*; Volkow, P (Mexico City, Mexico)

P002 Renal function in perinatally HIV-1-infected patients Al Hammoud, R*; Perez, N; Rodriguez, G; Benjamins, L; Del Bianco, G; Murphy, J; Heresi, G (Houston, TX, USA)

P003 Frequency and distribution of cardiometabolic comorbidities in clinically stable HIV patients on long-term ARV therapy in Lima-Callao, Peru Hidalgo, J*; Florez, A; Agurto, C; Pinedo, Y; Ayarza, R; Rodriguez, L; La Rosa, A; Gutierrez, R (Lima, Peru)

P004 Renal insufficiency in HIV/AIDS patients: 5-year experience in an intensive care unit Chediack, V; Ricart, J*; Sanchez Cunto, M; Dominguez, C; Mammoliti, G; Yesica, L; Nano, M; Gonzalez, L; Fernandez, J; Cunto, E; Nogueras, C (Buenos Aires, Argentina)

P005 AIDS-related pneumocystis jiroveci pneumonia in an intensive care unit: a descriptive study Ricart, J*; Sanchez Cunto, M; Chediack, V; Dominguez, C; Gregori Sabelli, R; Cortez, E; Fernandez, J; Velasquez Lopez, P; Caceres, S; Cunto, E (Buenos Aires, Argentina)

P006 Latin American prospective cohort of adult HIV-positive patients (LATINA): factors associated with presenting symptoms at diagnosis Rodriguez Loria, G*; Mosqueda, L; Andrade Villanueva, J; Losso, M; Viloria, G; Hercilla, L; Mantilla Suárez, M; Lopardo, G; Michaan, M; Sanchez, M; Belloso, W (Buenos Aires, Argentina)

P007 Latin American prospective cohort of adult HIV-positive patients (LATINA): 2017 baseline characteristics update Rodriguez Loria, G*; Mosqueda, L; Andrade Villanueva, J; Losso, M; Viloria, G; Hercilla, L; Mantilla Suárez, M; Lopardo, G; Michaan, M; Sanchez, M; Belloso, W (Buenos Aires, Argentina)

P008 Comorbidities in a sample of HIV-positive adults in Colombia. Sub-analysis of patients younger than 50 years Martínez, P; Ruiz, J; Beltran, C; Rojas, M; Leon, S*; Lenis, W (Bogotá, Colombia)

P009 Problems related to medication and clinical characteristics in patients older than 50 years with HIV/AIDS newly diagnosis Hoyos Pulgarin, J*; Ramirez Briñez, F; Restrepo, C; Quiceno, A; Alzate, J (Medellín, Colombia)

P010 Cardiovascular risk in elderly patients with HIV. Comparison of Framingham versus D:A:D cardiovascular risk calculators López Hernandez, M* (Mexico City, Mexico)

HIV/Hepatitis Co-infection

P011 Real-world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients co-infected with HCV and HIV-1 Buggisch, P; Moreno, A; Isakov, V; Backus, L; Ain, D; Gonzalez-Garcia, J; Naik, S; Mehta, S; Lee, J; Mertens, M; Llewellyn, J; Natha, M; Kersey, K; Osinusi, A; Slim, J; Zhdanov, K; Berenguer, J; Zeuzem, S; Mendez-Navarro, J* (Mexico City, Mexico)

14 15

POSTER PRESENTATIONS (continued)

P012 HCV treatment in HIV/HCV co-infection in Brazil, 2016–2017 Monzani Vivaldini, S*; Santos, M; Carlos Almeida, E; Alvarenga Pinto, F; Neri Gomes, J; Fernandes, N; Argia Basile Cattapan, E; Jacintho Mendes Correa, M; Moreira Rick, F; Mendes Pereira, G; Tonini, K; Oliveira Bernard, A; Schwartz Benzaken, A (Brasília, Brazil)

P013 Investigation of the increasing number of hepatitis A cases among men in the biggest city in Latin America in 2017 Jorge de Queiroz, M; Alvarenga Pinto, F*; Abrahão Ribeiro, R; Monzani Vivaldini, S; de Almeida Coelho, R; Mendes Pereira, G (Brasília, Brazil)

P014 Change of evaluation and treatment patterns over a 4-year period of direct-acting antiviral use in HIV/HCV co-infected patients Gonzales Zamora, J; Henry, Z* (Miami, FL, USA)

P015 HBV monoinfection and HIV/HBV co-infection in Brazil: what are the differences? Alvarenga Pinto, F*; Alves de Souza, F; Santos, M; Monzani Vivaldini, S; Jorge de Queiroz, M; Almeida, E; Mendes Pereira, G (Brasília, Brazil)

P016 Monitoring hepatitis B and C infections among HIV patients: a proposed model for a cascade of care in viral hepatitis in the Dominican Republic Tapia, L; Peña, P; Matos, Y; Valerio, K; Muñoz, M; Ledesma, J; Jimenez, M; Paulino-Ramirez, R* (Santo Domingo, Dominican Republic)

P017 Epidemiological characteristics of HIV-positive/hepatitis C virus (HCV) co-infection in Hispanic women Centeno-Alvarado, N*; Wojna, V; Ramos-Perez, E; Barreto, J; Rodriguez-Benitez, R (San Juan, Puerto Rico)

HIV and Tuberculosis

P019 Severe HIV-associated pulmonary tuberculosis, 2006–2016 Ricart, J*; Sanchez Cunto, M; Gregori Sabelli, R; Dominguez, C; Saul, P; Chomyn, J; Nano, M; Chacon, N; Chediack, V; Cunto, E (Buenos Aires, Argentina)

P021 HIV/TB co-infection Ciappina, A*; Bobatto, A; Bechini, F; Boggia, B; Echaide, M; Iriart, J; Lux, A; Urbina, L; Corral, G; Hualde, M; Miglioranza, C; Aquilia, S (Mar del Plata, Argentina)

HIV and Women, Including MTCT

P022 Prevalence of comorbid conditions in a cohort of women living with HIV in Argentina Mauas, R*; Laurido, M; Cabral, L; Cacciari, V; Cassetti, I (Buenos Aires, Argentina)

P023 Factors associated with virological failure in women with HIV Cabrera, T*; Ramos, U; Nava, C; Almaraz, A; Badial Hernández, F; Langarica, E; Gonzalez, A (Mexico City, Mexico)

HIV and Vulnerable Populations

P024 Overview of healthcare linkage, retention and adherence in young people living with HIV in Brazil Kolling, A*; Camelo Madeira de Moura, M; da Silva Netto, J; Vianna Brizolara, R; Pati Pascom, A; de Barros Perini, F; Schwartz Benzaken, A (Brasília, Brazil)

P025 Retention in care trends and viral suppression in newly admitted HIV patients in a tertiary centre in Mexico City Barlandas, E; Caro-Vega, Y; Belaunzarán-Zamudio, P; Guerrero-Torres, L; Sierra-Madero, J; Crabtree-Ramírez, B* (Mexico City, Mexico)

P027 Advanced presentation among HIV/AIDS patients despite universal access to antiretroviral therapy in northern Mexico Gonzalez-Fernandez, E*; Medina-Piñon, I; Ramos-Jimenez, J (Monterrey, Mexico)

P029 Cardiovascular risk assessment in transgender women in a HIV/STI clinic in a public hospital in Argentina Ballivian, J*; Toibaro, J; Viloria, G; Ivalo, S; Losso, M (Buenos Aires, Argentina)


16


16


P030 First intervention in a gay sauna with rapid tests for HIV infection in the city of Córdoba, Argentina Pedrola, M*; Haag, N; Garcia, J; Munoz, E; Bonilla, C; Alaniz, G; Laurido, M (Venado Tuerto, Argentina)

P033 Co-occurring psychosocial problems in transgender women living with HIV enrolled in a clinical trial in Argentina Aristegui, I; Radusky, P; Zalazar, V; Frola, C; Cardozo, N; Gun, A; Fojo, E; Romero, M; Cahn, P; Sued, O* (Buenos Aires, Argentina)

Models of Care/Scale-Up of Treatment

P035 The continuum of care among very immunosuppressed (less than 100 CD4+ cells) patients in an outpatient clinic in Mexico City: gaps in diagnosis, linkage and retention in care Piñeirúa-Menendez, A*; Del Hoyo, M; Osorno González de León, F; Badial Hernández, F; Niño-Vargas, R (Mexico City, Mexico)

P036 Prolonged hospital stay and associated factors in patients receiving care in a HIV/AIDS clinic in Mexico City Lara-Medrano, R*; Camiro-Zúñiga, A; Caro-Vega, Y; Crabtree-Ramírez, B; Sierra-Madero, J; Belaunzarán-Zamudio, P (Mexico City, Mexico)

P037 Vaccine coverage in adults living with HIV and receiving care in a tertiary care centre in Mexico City, 2005–2016 Mendez-Roldan, M*; Olmedo-Reneaum, A; Cano-Torres, J; Camiro-Zuñiga, A; Caro-Vega, Y; Galindo-Fraga, A; Huertas-Jimenez, M; Sierra-Madero, J; Belaunzarán-Zamudio, P (Mexico City, Mexico)

P038 HIV clinical monitoring in the southern region of Brazil Mendes Pereira, G; Abrahão Ribeiro, R*; Alvarenga Pinto, F (Brasília, Brazil)

P039 Advances in the management model for the provision of HIV genotyping services in Brazil Kohiyama, I*; Alonso, J; Pinho, R; Villares, M; Pires, A (Brasília, Brazil)

P040 Reduction of errors during the pre-analytical process for the collection of HIV samples in Mexican centres: a pilot study of a new software strategy implementation Rodriguez-Diaz, R*; Ramos-Hinojosa, A; Orta-Resendiz, A; Angulo-Medina, L; Gomez-Cuellar, J; Sierra-Madero, J; Soto-Ramirez, L (Mexico City, Mexico)

P041 The ‘no-show’ patients in HIV clinical care Sandoval, M*; Kundro, M; Losso, M (Buenos Aires, Argentina)

P042 Contribution of SISCEL/SICLOM systems for PLHA monitoring: CTA/environmental dermatology experience/SES/RS in Brazil Machado Alves, D*; Both, N; Torres de Carvalho, F; Alnoch, E; Castoldi, L; Canterle, G (Porto Alegre, Brazil)

P043 Provincial differences in the update status of antiretroviral treatments Soullas, G*; Biscay, A; Marovic, M; Mendizabal, M; Maulen, S, Pardo, P (Buenos Aires, Argentina)

Non-AIDS Morbidities and Mortality, and Ageing

P044 Low frequency of screening for anal carcinoma in a cohort of adult men receiving care for HIV in a third-care, referral centre in Mexico City Gomez-Garcia, L*; Belaunzarán-Zamudio, P; Crabtree-Ramírez, B; Sierra-Madero, J; Caro-Vega, Y (Mexico City, Mexico)

P045 Evaluation of cardiovascular risk factors in HIV patients in a public hospital Martini, S*; Falak, A; Aguilar, A; Sued, O; Cahn, P; Perez, H (Buenos Aires, Argentina)

P046 In which geographic areas should actions be targeted to reduce HIV/AIDS mortality in Mexico? An analysis of this magnitude, distribution and trends by Jurisdicción Sanitaria, 1990–2015 Bravo-García, E; Magis-Rodríguez, C*; Palacios-Martínez, M; Guarneros-Soto, N (Mexico City, Mexico)

16


17


Treatment Strategies and Outcomes

P047 Safety and efficacy of E/C/F/TAF in HIV-infected adults on chronic haemodialysis Eron Jr, J; Kalayjian, R; Wurapa, AK; Stephens, J; McDonald, C; Wilkin, A; McKellar, M; Custodio, J; Jiang, S; SenGupta, D; Espinoza, L*; Das, M (Foster City, CA, USA)

P048 Phase 3, randomised, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: Week 48 results Daar, E; DeJesus, E; Ruane, P; Crofoot, G; Creticos, C; Molina, J-M; Koenig, E; Liu, Y; Andreatta, K; Graham, H; Cheng, A; Martin, H; Silva, F*; Quirk, E (Foster City, CA, USA)

P049 Superior efficacy of dolutegravir (DTG) plus two nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus two NRTIs in second-line treatment: interim data from the DAWNING study Aboud, M; Kaplan, R; Lombaard, J; Zhang, F; Hidalgo, J; Mamedova, E; Losso, M*; Chetchotisakd, P; Sievers, J; Brown, D; Hopking, J; Underwood, M; Nascimento, MC; Gartland, M; Smith, K (Buenos Aires, Argentina)

P050 Monitoring HIV care in Brazil: a national strategy to reduce the HIV treatment gap Vianna Brizolara, R*; Kolling, A; da Silva Netto, J; Camelo Madeira de Moura, M; de Barros Perini, F; Schwartz Benzaken, A (Brasília, Brazil)

P051 Time of initiation of treatment of people living with HIV Uesono, J*; Eri Shimizu, H; Diáz Bermudez, X; Merchan-Hamann, E; Moreira Rick, F; Pati Pas, A (Brasília, Brazil)

P052 Salvage antiretroviral therapy for the treatment of HIV-1 infection in patients failing a first-line regimen: experience from a national peer advisory committee for physicians in Mexican HIV clinics Sánchez-Domínguez, J*; Ramírez-Hinojosa, J; Figueroa-Morales, A; Rivera-Villegas, H; Larrea-Schiavon, S; Calva, J; and the CORESAR Study Group (Mexico City, Mexico)

P053 Real-life use of raltegravir: experience from Hospital Guillermo Almenara, Lima, Peru Malpartida, O; Pérez-Lazo, G; Collins, J*; and the Almenara Hospital AIDS Working Group Medicina Interna 1-Infectología (Lima, Peru)

P054 The importance of the health team in the search for HIV-infected patients who abandoned treatment Carvalho, N* (São Paulo, Brazil)

Viral Hepatitis

P055 High rates of medical and psychiatric comorbidities in HIV/HCV co-infected patients treated with sofosbuvir-containing regimens in registrational clinical trials Sulkowski, M; Cooper, C; Molina, J-M; Naggie, S; Osinusi, A; Stamm, L; Massetto, B; McNally, J; Brainard, D; McHutchison, J; Wyles, D; Rockstroh, J; Dieterich, D; Bassetti, E; Campos, A* (São Paulo, Brazil)

P056 SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the Astral-1, Astral-2 and Astral-3 studies Agarval, K; Patel, K; Samuel, D; Bourliere, M; Liu, X; Younes, Z; Liu, L; McNally, J; Osinusi, A; Brainard, D; Subramanian, S; Afdhal, N; Cheinquer, N; Dutra, I* (São Paulo, Brazil)

P057 Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment Eric, L; Landis, C; Maliakkal, B; Bonacini, M; Ortiz-Lasanta, G; Zhang, J; Mogalian, E; De-Oertel, S; Osinusi, A; Brainard, D; McHutchison, J; Flamm, S; Gordon, S; Gane, E; Chirino, R* (Mexico City, Mexico)

P058 Genetic diversity of the hepatitis B virus strains in Cuba: absence of West-African genotypes despite the transatlantic slave trade Rodriguez Lay, L*; Bello Corredor, M; Montalvo Villalba, M; Sariego Frometa, S; Sanchez Wong, M; Valdes Alonso, L; Samada, M; Sausy, A; Hübschen, J; Muller, C (Havana, Cuba)

1818


P059 Analysis of risk factors associated with hepatitis B infection in Paraná correctional institutions in Brazil Ferreto, L*; Follador, F; Vieira, A; Bento Casaril, K; Coelho, H; Torres, R; Frois, J; Amaral, G; Yamada, R (Francisco Beltrão, Brazil)

P060 Anti-HCV seroprevalence and risk factors of HCV infection in penitentiaries in Paraná, Brazil Ferreto, L*; Follador, F; Vieira, A; Coelho, H; Yamada, R; Torres, R; Frois, J; Amaral, G (Francisco Beltrão, Brazil)

P061 Perceptions of hepatitis B and hepatocellular carcinoma among Blacks in South Florida Gonzalez-Diaz, J*; Schaefer Solle, N; Martin, P; Kobetz, E; Jones, P (Miami, FL, USA)

P062 Hepatitis B: detection rates and vaccination coverage in Brazil in 2016 Alvarenga Pinto, F*; Santos, M; de Almeida Coelho, R; Monzani Vivaldini, S; Mendes Pereira, G; Schwartz Benzaken, A (Brasília, Brazil)

P063 Android applications for viral hepatitis diagnosis, research and training Guadis Salazar, E*; Rodriguez Lay, L; Montalvo Villalba, M; Bello Corredor, M; Lopez Hernandez, D; Marrero Sanchez, B; Sanchez Puente, W (Havana, Cuba)

P064 Emergence of the transmitted resistance of HIV-1 to antiretroviral drugs in Cuban patients during the period 2009–2016 Machado Zaldivar, L*; Díaz Torres, H; Blanco de Armas, M; Dubed Echevarria, M; Ruiz, N; Martínez, L; Silva Cabrera, E; López Rizo, L; Romay Franchi, D; Valdés de Calzadilla, N; Nibot, C; Rivero Martínez, C; Joanes Fiol, J; Cancio, I; Rodríguez Acosta, M (San José de las Lajas, Cuba)

Virology and Immunology

P065 Plasma cytokines levels in patients with disseminated Kaposi sarcoma with syphilis and infectious AIDS-defining events Volkow, P; Ramon-Luing, L; Chávez-Galán, L; Cornejo-Juárez, P; Vilar-Compte, D; Ocaña-Guzmán, R; Islas-Muñoz, B* (Mexico City, Mexico)

P066 Co-receptor tropism determined by genotypic assay in HIV-1 non-B subtypes circulating in Cuba. Implications for pathogenesis and maraviroc resistance Kourí, V*; Pérez, L; Martínez, Y; Aleman, Y; Diaz, D; Han, R; Pintos, Y; Mendez, M; Soto, Y; Baños, Y; Caturla, Y; Fonseca, C; Pérez, J; Hengge, U (Havana, Cuba)


programme overview - hiv & hep...

Documents